ライフキャリアから診る1型糖尿病

出版社： 中外医学社
著者：
発行日： 2023-05-10
分野： 臨床医学：内科  >  糖尿病
ISBN： 9784498223028
電子書籍版： 2023-05-10 （1版1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：4～8営業日

4,180 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

4,180 円(税込)

購入する

商品紹介

1型糖尿病診療のスペシャリストたちが，臨床現場で役に立つエビデンスと経験を惜しげもなく披露します．ライフキャリアレインボーを軸に，食事・運動・薬物療法はもちろん，生活や病態のステージ別に，「1型糖尿病を持つ人をいかに支えていくか」のリアルをお伝えします．移行期は？　仕事は？　結婚は？　出産は？　などの多様な疑問に対し，スペシャリストたちがどう考えていくのかをぜひご覧ください．

目次

  • I　総論

    1　1型糖尿病の治療と心理社会的支援の必要性
    　　　「糖尿病」はなぜ重要な病気なのか
    　　　インスリン発見以降の1型糖尿病
    　　　1型糖尿病の病態
    　　　1型糖尿病は予防または根治できるのか
    　　　1型糖尿病の発症年齢
    　　　1型糖尿病と女性
    　　　1型糖尿病の経済的負担
    　　　1型糖尿病に欠かせない心理社会的支援

    2　1型糖尿病ライフキャリアレインボーの提案
    　　　ライフキャリアレインボーとは
    　　　1型糖尿病ライフキャリアレインボーの描き方
    　　　ライフキャリアレインボーを用いた1型糖尿病ライフプランニング
    　　　1型糖尿病ライフキャリアレインボーのテンプレート

    ［コラム］1型と2型の分類は妥当か？
    　　　1型と2型の境界線
    　　　糖尿病の再分類プロジェクト

    II　1型糖尿病治療の理論Up-to-Date

    1　頻回注射法
    　　　インスリン発見から100周年
    　　　インスリン注入デバイスと手技
    　　　頻回注射法
    　　　補正インスリンと残存インスリン
    　　　暁現象とソモジー効果
    　　　食後高血糖の原因と対処法
    　　　月経周期による月内血糖変動への対処法
    　　　アイデンティティーに応じた自由なMDI
    　　　インスリン注射療法のアドヒアランスの問題
    　　　MDIとCSIIの長所・短所を知って選択する

    2　CSII・SAP
    　　　CSIIの適応について
    　　　入院/外来での導入
    　　　CSII症例の病診連携
    　　　ポンプ診療の実際
    　　　CSII，SAPの今後

    3　SMBGとCGM
    　　　血糖自己測定（SMBG）の登場
    　　　SMBGの限界
    　　　CGM：血糖測定は点から線の時代へ
    　　　CGMメトリクス
    　　　AGPレポート
    　　　管理栄養士による指導
    　　　健康運動指導士による指導
    　　　看護師・医師による指導
    　　　CGMメトリクスの時系列：血糖測定は線から面へ

    4　カーボカウント〈黒田暁生，松久宗英〉
    　　　1型糖尿病における食事用のインスリンの基本
    　　　カーボカウントとは
    　　　黒田式カーボカウントの紹介
    　　　低血糖での対応
    　　　応用カーボカウントに進む前にインスリンの打ち方を知る
    　　　応用カーボカウント
    　　　外食を食べるときの対応法
    　　　脂質，タンパク質の多い食事での対応方法
    　　　経験則

    5　スポーツ
    　　　運動生理
    　　　運動時の実際の注意点と私の体験

    6　SGLT2阻害薬
    　　　1型糖尿病におけるSGLT2阻害薬の有効性
    　　　1型糖尿病におけるSGLT2阻害薬の安全性
    　　　推定されるケトアシドーシスの発症機序とリスク因子
    　　　1型糖尿病患者へのSGLT2阻害薬処方時のリスクマネージメント

    7　低血糖とDKA
    　　　低血糖症
    　　　糖尿病性ケトアシドーシス（DKA）

    8　血管合併症
    　　　1型糖尿病における合併症の疫学Up-to-Date
    　　　ジョスリン50年メダリスト研究
    　　　1型糖尿病の肥満
    　　　併存疾患の管理

    9　骨折
    　　　1型糖尿病と骨折（疫学）
    　　　なぜ1型糖尿病で骨折が多いのか（メカニズム）
    　　　どのように予防，診断，治療するか

    ［コラム］根治を目指す取り組み～移植医療・再生医療～
    　　　1型糖尿病の根治とは？
    　　　膵β細胞からみて
    　　　ジョスリン50年メダリスト研究
    　　　膵β細胞を増やすには～ヒト膵島研究～
    　　　1型糖尿病に対する移植医療
    　　　1型糖尿病に対する再生医療

    III　1型糖尿病を取り巻く社会環境

    1　仕事
    　　　1型糖尿病における「スティグマ」と「アドボカシー」
    　　　1型糖尿病におけるスティグマの実態調査
    　　　私にとっての1型糖尿病の「スティグマ」と「アドボカシー」を振り返る

    ［患者の声］患者家族としてどう糖尿病と向き合ったか
    ［患者の声］相棒とともに歩む

    2　結婚・妊娠・出産
    　　　結婚
    　　　妊娠に備えて
    　　　妊娠中の過ごし方
    　　　出産と子育て

    ［患者の声］妊娠をきっかけに受け入れられた1型糖尿病
    ［患者の声］ワタシらしくいるために
    ［コラム］1型糖尿病の患者さんの心理を考える

    IV　1型糖尿病治療の実際

    1　発症直後
    　　　1型糖尿病と診断を受けた者の想い
    　　　慢性期医療を見据えた急性期の糖尿病教育
    　　　発症初期の1型糖尿病ケアのポイント
    　　　発症後の1型糖尿病教育ツール
    　　　発症時に注意すべき身体的な変化
    　　　ハネムーン期とその終焉
    　　　その他の自己免疫疾患を見落とさない
    　　　高齢発症1型糖尿病

    2　小児思春期（成長）
    　　　幼児期
    　　　学童期
    　　　思春期
    　　　移行について
    　　　ディスカッションウィズ・コロナ時代のサマーキャンプ
    　　　はじめに
    　　　リアルのサマーキャンプができずに困っていること
    　　　失われて知るキャンプの大切さ
    　　　ニューノーマル下でのキャンプ再開の条件
    　　　オンラインキャンプを魅力的なものにするために

    3　移行期（自立）
    　　　慢性疾患を持つ子どもの自律と自立
    　　　1型糖尿病に成人医療への診療移行は必要か
    　　　本邦における移行期医療の現状
    　　　自立を支援し，成人科への診療移行を円滑に行うために
    　　　成人期医療移行チェックリストについて

    ［コラム］小児思春期糖尿病と自立に向けての取り組み
    　　　チェックリストの作成（幼児期・学童前期・学童後期）
    　　　母親のケア
    　　　ライフスタイルに応じた糖尿病ケア

    4　成人期（確立・維持）
    　　　1型糖尿病は不幸？
    　　　糖尿病による健康リスクの低減
    　　　糖尿病に対する正しい認識の浸透
    　　　経済的負担の軽減

    5　高齢者（衰退）〈前田泰孝〉
    　　　1型糖尿病人口の高齢化
    　　　高齢1型糖尿病の精神身体的問題
    　　　高齢1型糖尿病の社会的問題
    　　　人生観を尊重した血糖コントロール目標
    　　　高齢1型糖尿病の治療ガイドライン

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 総論

P.9 掲載の参考文献
1) Kawasaki E. Type 1 diabetes and autoimmunity. Clin Pediatr Endocrinol. 2014 ; 23 : 99-105.
 
2) Makimattila S, Harjutsalo V, Forsblom C, et al ; FinnDiane Study Group. Every fifth individual with type 1 diabetes suffers from an additional autoimmune disease : a Finnish nationwide study. Diabetes Care. 2020 ; 43 : 1041-7.
 
3) Carstensen B, Read SH, Friis S, et al ; Diabetes and Cancer Research Consortium. Cancer incidence in persons with type 1 diabetes : a five-country study of 9,000 cancers in type 1 dia betic individuals. Diabetologia. 2016 ; 59 : 980-8.
 
4) Patterson CC, Harjutsalo V, Rosenbauer J, et al. Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 European centres in the 25 year period 1989-2013 : a multicentre prospective registration study. Diabetologia. 2019 ; 62 : 408-17.
 
5) Roep BO, Thomaidou S, van Tienhoven R, et al. Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?). Nat Rev Endocrinol. 2021 ; 17 : 150-61.
 
6) Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group ; Krischer JP, Schatz DA, Bundy B, et al. Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes : a randomized clinical trial. JAMA. 2017 ; 318 : 1891-902.
 
7) Skyler JS. Prevention and reversal of type 1 diabetes--past challenges and future opportunities. Diabetes Care. 2015 ; 38 : 997-1007.
 
8) Stewart CJ, Ajami NJ, O'Brien JL, et al. Temporal development of the gut microbiome in early childhood from the TEDDY study. Nature. 2018 ; 562 : 583-8.
 
9) Vatanen T, Franzosa EA, Schwager R, et al. The human gut microbiome in early-onset type 1 diabetes from the TEDDY study. Nature. 2018 ; 562 : 589-94.
 
10) Vehik K, Lynch KF, Wong MC, et al ; TEDDY Study Group. Prospective virome analyses in young children at increased genetic risk for type 1 diabetes. Nat Med. 2019 ; 25 : 1865-72.
 
11) Unsworth R, Wallace S, Oliver NS, et al. New-onset type 1 diabetes in children during COVID-19 : multicenter regional findings in the U.K. Diabetes Care. 2020 ; 43 : e170-1.
 
12) Thomas NJ, Jones SE, Weedon MN, et al. Frequency and phenotype of type 1 diabetes in the first six decades of life : a cross-sectional, genetically stratified survival analysis from UK Biobank. Lancet Diabetes Endocrinol. 2018 ; 6 : 122-9.
 
13) Thunander M, Petersson C, Jonzon K, et al. Incidence of type 1 and type 2 diabetes in adults and children in Kronoberg, Sweden. Diabetes Res Clin Pract. 2008 ; 82 : 247-55.
 
14) Warram JH, Krolewski AS, Kahn CR. Determinants of IDDM and perinatal mortality in children of diabetic mothers. Diabetes. 1988 ; 37 : 1328-34.
 
15) Mathiesen ER, Ali N, Alibegovic AC, et al. Risk of major congenital malformations or perinatal or neonatal death with insulin detemir versus other basal insulins in pregnant women with preexisting diabetes : the real-world EVOLVE study. Diabetes Care. 2021 ; 44 : 2069-77.
 
16) Katz ML, Volkening LK, Butler DA, et al. Family-based psychoeducation and Care Ambassador intervention to improve glycemic control in youth with type 1 diabetes : a randomized trial. Pediatr Diabetes. 2014 ; 15 : 142-50.
 
17) Svoren BM, Butler D, Levine BS, et al. Reducing acute adverse outcomes in youths with type 1 diabetes : a randomized, controlled trial. Pediatrics. 2003 ; 112 : 914-22.
 
P.20 掲載の参考文献
1) Ahlqvist E, Storm P, Karajamaki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes : a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018 ; 6 : 361-9.
PubMed
2) Tanabe H, Saito H, Kudo A, et al. Factors associated with risk of diabetic complications in novel cluster-based diabetes subgroups : a Japanese retrospective cohort study. J Clin Med. 2020 ; 9 : 2083.
 

II 1型糖尿病治療の理論Up - to - Date

P.30 掲載の参考文献
1) Shilo S, Godneva A, Rachmiel M, et al. Prediction of personal glycemic responses to food for individuals with type 1 diabetes through integration of clinical and microbial data. Diabetes Care. 2022 ; 45 : 502-11.
 
2) Bell KJ, Fio CZ, Twigg S, et al. Amount and type of dietary fat, postprandial glycemia, and insulin requirements in type 1 diabetes : a randomized within-subject trial. Diabetes Care. 2020 ; 43 : 59-66.
 
3) Lee SR, Choi WY, Heo JH, et al. Progesterone increases blood glucose via hepatic progesterone receptor membrane component 1 under limited or impaired action of insulin. Sci Rep. 2020 ; 10 : 1-11.
 
4) Soupal J, Petruzelkova L, Grunberger G, et al. Glycemic outcomes in adults with T1D are impacted more by continuous glucose monitoring than by insulin delivery method : 3 years of follow-up from the COMISAIR study. Diabetes Care. 2020 ; 43 : 37-43.
 
P.42 掲載の参考文献
1) Scheiner G, Boyer BA. Characteristics of basal insulin requirements by age and gender in Type-1 diabetes patients using insulin pump therapy. Diabetes Res Clin Pract. 2005 ; 69 : 14-21.
 
2) Kuroda A, Kaneto H, Shimomura I, et al. Basal insulin requirement is ~30% of the total daily insulin dose in type 1 diabetic patients who use the insulin pump. Diabetes Care. 2011 ; 34 : 1089-90.
 
3) Matsuoka A, Hirota Y, Ogawa W, et al. Effect of switching from conventional continuous subcutaneous insulin infusion to sensor augmented pump therapy on glycemic profile in Japanese patients with type 1 diabetes. Diabetol Int. 2018 ; 9 : 201-7.
 
4) Thethi TK, Rao A, Fonseca V, et al. Consequences of delayed pump infusion line change in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion. J Diabetes Complications. 2010 ; 24 : 73-8.
 
5) Mensh BD, Winiewski NA, Neil BM, et al. Susceptibility of interstitial continuous glucose monitor performance to sleeping position. J Diabetes Sci Technol. 2013 ; 7 : 863-70.
 
P.54 掲載の参考文献
1) Danne T, Nimri R, Battelino T, et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017 ; 40 : 1631-40.
 
2) Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation : recommendations from the international consensus on time in range. Diabetes Care. 2019 ; 42 : 1593-603.
 
3) Kennedy A, Nirantharakumar K, Chimen M, et al. Does exercise improve glycaemic control in type 1 diabetes? A systematic review and meta-analysis. PLoS One. 2013 ; 8 : e58861.
 
4) Brazeau AS, Rabasa-Lhoret R, Strychar I, et al. Barriers to physical activity among patients with type 1 diabetes. Diabetes Care. 2008 ; 31 : 2108-9.
 
P.63 掲載の参考文献
1) 黒田暁生, 長井直子, 小西祐子, 他. 食品交換表に基づく新たなカーボカウント指導法. 糖尿病. 2010 ; 53 : 391-5.
 
2) 黒田暁生, 丸山千寿子, 松久宗英. 第7版 食品交換表に基づいた炭水化物50～60%での主食以外の炭水化物含有量. 糖尿病. 2014 ; 57 : 921-2.
 
3) http://www.adaendo.com/davidson/SanAntonio030502frnt.ppt
 
4) Edqvist J, Rawshani A, Adiels M, et al. BMI, mortality, and cardiovascular outcomes in type 1 diabetes : findings against an obesity paradox. Diabetes Care. 2019 ; 42 : 1297-304.
 
5) Porcellati F, Rossetti P, Ricci NB, et al. Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes. Diabetes Care. 2007 ; 30 : 1261-3.
 
6) Kuroda A, Yasuda T, Takahara M, et al. Carbohydrate-to-insulin ratio is estimated from 300-400 divided by total daily insulin dose in type 1 diabetes patients who use the insulin pump. Diabetes Technol Ther. 2012 ; 14 : 1077-80.
 
P.72 掲載の参考文献
1) Kaufman FR, Boranian E. 雨宮伸, 難波光義, 監訳. インスリンポンプとCGM-糖尿病をうまく管理するためのガイド. 第2版. 東京 : 医歯薬出版 ; 2020. p.105-21.
 
2) Martin-Timon I, Del Canizo-Gomez FJ. Mechanisms of hypoglycemia unawareness and implications in diabetic patients. World J Diabetes. 2015 ; 6 : 912-26.
 
3) McMahon SK, Ferreira LD, Ratnam N, et al. Glucose requirements to maintain euglycemia after moderate-intensity afternoon exercise in adolescents with type 1 diabetes are increased in a biphasic manner. J Clin Endocrinol Metabol. 2007 ; 92 : 963-8.
 
4) Riddell MC, Gallen IW, Smart CE, et al. Exercise management in type 1 diabetes : a consensus statement. Lancet Diabetes Endocrinol. 2017 ; 5 : 377-90.
 
5) Rabasa-Lhoret R, Bourque J, Ducros F, et al. Guidelines for premeal insulin dose reduction for postprandial exercise of different intensities and durations in type 1 diabetic subjects treated intensively with a basal-bolus insulin regimen (ultralente-lispro). Diabetes Care. 2001 ; 24 : 625-30.
 
6) Admon G, Weinstein Y, Falk B, et al. Exercise with and without an insulin pump among children and adolescents with type 1 diabetes mellitus. Pediatrics. 2005 ; 6 : 348-55.
 
7) Yardley JE, Kenny GP, Perkins BA, et al. Effects of performing resistance exercise before versus after aerobic exercise on glycemia in type 1 diabetes. Diabetes Care. 2012 ; 35 : 669-75.
 
P.80 掲載の参考文献
1) Yamada T, Shojima N, Noma H, et al. Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus : Systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018 ; 20 : 1755-61.
 
2) Kaku K, Isaka H, Sakatani T, et al. Long-term (52-week) efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus : An uncontrolled, open-label extension of a phase 3 study. J Diabetes Investig. 2020 ; 11 : 662-71.
 
3) Mathieu C, Dandona P, Phillip M, et al. Glucose variables in type 1 diabetes studies with dapagliflozin : pooled analysis of continuous glucose monitoring data from DEPICT-1 and -2. Diabetes Care. 2019 ; 42 : 1081-7.
 
4) Chiba K, Nomoto H, Nakamura A, et al. Sodium-glucose cotransporter 2 inhibitors reduce day-to-day glucose variability in patients with type 1 diabetes. J Diabetes Investig. 2021 ; 12 : 176-83.
 
5) Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020 ; 383 : 1436-46.
PubMed
6) McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019 ; 381 : 1995-2008.
PubMed
7) Danne T, Garg S, Peters AL, et al. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care. 2019 ; 42 : 1147-54.
 
8) Recommendations on the proper use of SGLT2 inhibitors. Diabetol Int. 2020 ; 11 : 1-5.
 
9) Patel NS, Van Name MA, Cengiz E, et al. Altered patterns of early metabolic decompensation in type 1 diabetes during treatment with a SGLT2 inhibitor : an insulin pump suspension study. Diabetes Technol Ther. 2017 ; 19 : 618-22.
 
10) Garg SK, Peters AL, Buse JB, et al. Strategy for mitigating DKA risk in patients with type 1 diabetes on adjunctive treatment with SGLT inhibitors : a STICH protocol. Diabetes Technol Ther. 2018 ; 20 : 571-5.
 
P.90 掲載の参考文献
1) Secrest AM, Becker DJ, Kelsey SF, et al. Cause-specific mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes. Diabetes. 2010 ; 59 : 3216-22.
 
2) Skrivarhaug T, Bangstad HJ, Stene LC, et al. Long-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway. Diabetologia. 2006 ; 49 : 298-305.
 
3) Laing SP, Swerdlow AJ, Slater SD, et al. The British Diabetic Association Cohort Study, I : allcause mortality in patients with insulin-treated diabetes mellitus. Diabet Med. 1999 ; 16 : 459-65.
 
4) Lind M, Svensson AM, Rosengren A. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med. 2015 ; 372 : 880-1.
 
5) Weinstock RS, DuBose SN, Bergenstal RM, et al ; T1D Exchange Severe Hypoglycemia in Older Adults With Type 1 Diabetes Study Group. Risk factors associated with severe hypoglycemia in older adults with type 1 diabetes. Diabetes Care. 2016 ; 39 : 603-10.
 
6) 難波光義, 岩倉敏夫, 西村理明, 他. 糖尿病治療に関連した重症低血糖の調査委員会報告. 糖尿病. 2017 ; 60 : 826-42.
 
7) International Hypoglycaemia Study Group. Hypoglycaemia, cardiovascular disease, and mortality in diabetes : epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol. 2019 ; 7 : 385-96. Erratum in : Lancet Diabetes Endocrinol. 2019 ; 7 : e18.
 
8) Matuleviciene-Anangen V, Rosengren A, Svensson AM, et al. Glycaemic control and excess risk of major coronary events in persons with type 1 diabetes. Heart. 2017 ; 103 : 1687-95.
 
9) Lacy ME, Gilsanz P, Eng C, et al. Severe hypoglycemia and cognitive function in older adults with type 1 diabetes : the study of longevity in diabetes (SOLID). Diabetes Care. 2020 ; 43 : 541-8.
 
10) Cukierman-Yaffe T, Bosch J, Jung H, et al. Hypoglycemia and incident cognitive dysfunction : a post hoc analysis from the ORIGIN trial. Diabetes Care. 2019 ; 42 : 142-7.
 
11) Puente EC, Silverstein J, Bree AJ, et al. Recurrent moderate hypoglycemia ameliorates brain damage and cognitive dysfunction induced by severe hypoglycemia. Diabetes. 2010 ; 59 : 1055-62.
 
12) Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol. 1998 ; 116 : 874-86. Erratum in : Arch Ophthalmol. 1998 ; 116 : 1469.
 
13) Lind M, Pivodic A, Svensson AM, et al. HbA1c level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes : Swedish population based cohort study. BMJ. 2019 ; 366 : l4894.
 
14) Shepard JA, Vajda K, Nyer M, et al. Understanding the construct of fear of hypoglycemia in pediatric type 1 diabetes. J Pediatr Psychol. 2014 ; 39 : 1115-25.
 
15) Barnard K, Thomas S, Royle P, et al. Fear of hypoglycaemia in parents of young children with type 1 diabetes : a systematic review. BMC Pediatr. 2010 ; 10 : 50.
 
16) Ahola AJ, Saraheimo M, Freese R, et al ; FinnDiane Study Group. Fear of hypoglycaemia and self-management in type 1 diabetes. J Clin Transl Endocrinol. 2016 ; 4 : 13-8.
 
17) Benoit SR, Zhang Y, Geiss LS, et al. Trends in diabetic ketoacidosis hospitalizations and in-hospital mortality -- United States, 2000-2014. MMWR. 2018 ; 67 : 362-5.
 
18) Glaser N, Barnett P, McCaslin I, et al ; Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. Risk factors for cerebral edema in children with diabetic ketoacidosis. The Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. N Engl J Med. 2001 ; 344 : 264-9.
 
19) Nyenwe EA, Kitabchi AE. The evolution of diabetic ketoacidosis : An update of its etiology, pathogenesis and management. Metabolism. 2016 ; 65 : 507-21.
 
P.95 掲載の参考文献
1) Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology. 1984 ; 91 : 1464-74.
 
2) Roy MS, Klein R, O'Colmain BJ, et al. The prevalence of diabetic retinopathy among adult type 1 diabetic persons in the United States. Arch Ophthalmol. 2004 ; 122 : 546-51.
 
3) DCCT/EDIC Research Group, Nathan DM, Bebu I, Hainsworth D, et al. Frequency of evidence-based screening for retinopathy in type 1 diabetes. N Engl J Med. 2017 ; 376 : 1507-16.
 
4) Perkins BA, Bebu I, de Boer IH, et al ; Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Risk factors for kidney disease in type 1 diabetes. Diabetes Care. 2019 ; 42 : 883-90.
 
5) Andresdottir G, Jensen ML, Carstensen B, et al. Improved prognosis of diabetic nephropathy in type 1 diabetes. Kidney Int. 2015 ; 87 : 417-26.
 
6) Mizokami-Stout KR, Li Z, Foster NC, et al ; for T1D Exchange Clinic Network ; T1D Exchange Clinic Network. The contemporary prevalence of diabetic neuropathy in type 1 diabetes : findings from the T1D exchange. Diabetes Care. 2020 ; 43 : 806-12.
 
7) Jeyam A, McGurnaghan SJ, Blackbourn LAK, et al ; SDRNT1BIO Investigators. Diabetic neuropathy is a substantial burden in people with type 1 diabetes and is strongly associated with socioeconomic disadvantage : a population-representative study from Scotland. Diabetes Care. 2020 ; 43 : 734-42.
 
8) Yokomizo H, Maeda Y, Park K, et al. Retinol binding protein 3 is increased in the retina of patients with diabetes resistant to diabetic retinopathy. Sci Transl Med. 2019 ; 11 : eaau6627.
 
9) Qi W, Keenan HA, Li Q, et al. Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunction. Nat Med. 2017 ; 23 : 753-62.
 
10) Gordin D, Harjutsalo V, Tinsley L, et al. Differential association of microvascular attributions with cardiovascular disease in patients with long duration of type 1 diabetes. Diabetes Care. 2018 ; 41 : 815-22.
 
11) Edqvist J, Rawshani A, Adiels M, et al. BMI, mortality, and cardiovascular outcomes in type 1 diabetes : findings against an obesity paradox. Diabetes Care. 2019 ; 42 : 1297-304.
 
12) Corbin KD, Driscoll KA, Pratley RE, et al ; Advancing Care for Type 1 Diabetes and Obesity Network (ACT1ON). Obesity in type 1 diabetes : pathophysiology, clinical impact, and mechanisms. Endocr Rev. 2018 ; 39 : 629-63.
 
13) Wang W, Liu H, Xiao S, et al. Effects of insulin plus glucagon-like peptide-1 receptor agonists (GLP-1RAs) in treating type 1 diabetes mellitus : a systematic review and meta-analysis. Diabetes Ther. 2017 ; 8 : 727-38.
 
14) Orchard TJ, Forrest KY, Kuller LH, et al ; Pittsburgh Epidemiology of Diabetes Complications Study. Lipid and blood pressure treatment goals for type 1 diabetes : 10-year incidence data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care. 2001 ; 24 : 1053-9.
 
15) Doria A, Galecki AT, Spino C, et al ; PERL Study Group. Serum urate lowering with allopurinol and kidney function in type 1 diabetes. N Engl J Med. 2020 ; 382 : 2493-503.
 
16) Inoguchi T, Sonoda N, Maeda Y. Bilirubin as an important physiological modulator of oxidative stress and chronic inflammation in metabolic syndrome and diabetes : a new aspect on old molecule. Diabetol Int. 2016 ; 7 : 338-41.
 
17) Inoguchi T, Sasaki S, Kobayashi K, et al. Relationship between Gilbert syndrome and prevalence of vascular complications in patients with diabetes. JAMA. 2007 ; 298 : 1398-400.
 
18) Inoguchi T, Sonta T, Tsubouchi H, et al. Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes : role of vascular NAD (P) H oxidase. J Am Soc Nephrol. 2003 ; 14 (8 Suppl 3) : S227-32.
 
19) Tang WHW, McGee P, Lachin JMJ, et al ; DCCT/EDIC Research Group. Oxidative stress and cardiovascular risk in type 1 diabetes mellitus : insights from the DCCT/EDIC Study. J Am Heart Assoc. 2018 ; 7 : e008368.
 
P.106 掲載の参考文献
1) 骨粗鬆症の予防と治療ガイドライン作成委員会. 骨粗鬆症の予防と治療ガイドライン 2015年版. 東京 : ライフサイエンス出版 ; 2015.
 
2) Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women : an observational study. Lancet. 1999 ; 353 : 878-82.
 
3) Janghorbani M, Van Dam RM, Willett WC, et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007 ; 166 : 495-505.
 
4) Vilaca T, Schini M, Harnan S, et al. The risk of hip and non-vertebral fractures in type 1 and type 2 diabetes : A systematic review and meta-analysis update. Bone. 2020 ; 137 : 115457.
 
5) Weber DR, Haynes K, Leonard MB, et al. Type 1 diabetes is associated with an increased risk of fracture across the life span : a population-based cohort study using The Health Improvement Network (THIN). Diabetes Care. 2015 ; 38 : 1913-20.
 
6) Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis. Osteoporos Int. 2007 ; 18 : 427-44.
PubMed
7) Hygum K, Starup-Linde J, Harslof T, et al. Mechanisms in endocrinology : diabetes mellitus, a state of low bone turnover - a systematic review and meta-analysis. Eur J Endocrinol. 2017 ; 176 : R137-57.
 
8) Leanza G, Maddaloni E, Pitocco D, et al. Risk factors for fragility fractures in type 1 diabetes. Bone. 2019 ; 125 : 194-9.
 
9) Thayakaran R, Perrins M, Gokhale KM, et al. Impact of glycaemic control on fracture risk in 5368 people with newly diagnosed Type 1 diabetes : a time-dependent analysis. Diabet Med. 2019 ; 36 : 1013-9.
 
10) Komorita Y, Minami M, Maeda Y, et al. Prevalence of bone fracture and its association with severe hypoglycemia in Japanese patients with type 1 diabetes. BMJ Open Diabetes Res Care. 2021 ; 9 : e002099.
 
11) Komorita Y, Iwase M, Fujii H, et al. Both hypo- and hyperglycaemia are associated with increased fracture risk in Japanese people with type 2 diabetes : the Fukuoka Diabetes Registry. Diabet Med. 2020 ; 37 : 838-47.
 
P.110 掲載の参考文献
1) Herold KC, Usmani-Brown S, Ghazi T, et al. Beta cell death and dysfunction during type 1 diabetes development in at-risk individuals. J Clin Invest. 2015 ; 125 : 1163-73.
 
2) Keenan HA, Sun JK, Levine J, et al. Residual insulin production and pancreatic ss-cell turnover after 50 years of diabetes : Joslin Medalist Study. Diabetes. 2010 ; 59 : 2846-53.
 
3) Yu MG, Keenan HA, Shah HS, et al. Residual beta cell function and monogenic variants in long-duration type 1 diabetes patients. J Clin Invest. 2019 ; 129 : 3252-63.
 
4) Pagliuca FW, Millman JR, Gurtler M, et al. Generation of functional human pancreatic beta cells in vitro. Cell. 2014 ; 159 : 428-39.
 
5) Veres A, Faust AL, Bushnell HL, et al. Charting cellular identity during human in vitro beta-cell differentiation. Nature. 2019 ; 569 : 368-73.
 
6) Yoshihara E, O'Connor C, Gasser E, et al. Immune-evasive human islet-like organoids ameliorate diabetes. Nature. 2020 ; 586 : 606-11.
 
7) Yamaguchi T, Sato H, Kato-Itoh M, et al. Interspecies organogenesis generates autologous functional islets. Nature. 2017 ; 542 : 191-6.
PubMed
8) Koike H, Iwasawa K, Ouchi R, et al. Modelling human hepato-biliary-pancreatic organogenesis from the foregut-midgut boundary. Nature. 2019 ; 574 : 112-6.
 

III 1型糖尿病を取り巻く社会環境

P.119 掲載の参考文献
1) 厚生労働省. 事業場における治療と仕事の両立支援のためのガイドライン. 令和4年3月改訂版. 2022. p.46-50.
 
2) Charleer S, De Block C, Van Huffel L, et al. Quality of life and glucose control after 1 year of nationwide reimbursement of intermittently scanned continuous glucose monitoring in adults living with type 1 diabetes (FUTURE) : a prospective observational real-world cohort study. Diabetes Care. 2020 ; 43 : 389-97.
 
3) プレスリリース. 日本糖尿病学会・日本糖尿病協会 アドボカシー委員会設立. https://www.nittokyo.or.jp/uploads/files/PR54_advocacy.pdf
 
4) 厚生労働科学研究費補助金 (循環器疾患・糖尿病等生活習慣病対策政策研究事業) 分担研究報告書. 1型糖尿病患者 (現在20歳以上) における日常・社会生活についての調査に関する研究. p.29-40
 
5) 厚生労働省. 企業・医療機関連携マニュアル. 令和3年3月改訂版. 2021. p.176-201.
 
P.128 掲載の参考文献
1) Dahlquist G, Blom L, Holmgren G, et al. The epidemiology of diabetes in Swedish children 0-14 years--a six-year prospective study. Diabetologia. 1985 ; 28 : 802-8.
 
2) Pociot, F, Lernmark A. Genetic risk factors for type 1 diabetes. Lancet. 2016 ; 387 : 2331-9.
 
3) Ziegler AG, Hillebrand B, Rabl W, et al. On the appearance of islet associated autoimmunity in offspring of diabetic mothers : a prospective study from birth. Diabetologia. 1993 ; 36 : 402-8.
 
4) Hyttinen V, Kaprio J, Kinnunen L, et al. Genetic liability of type 1 diabetes and the onset age among 22,650 young Finnish twin pairs : a nationwide follow-up study. Diabetes. 2003 ; 52 : 1052-5.
 
5) Nielsen GL, Moller M, Sorensen HT. HbA1c in early diabetic pregnancy and pregnancy outcomes : a Danish population-based cohort study of 573 pregnancies in women with type 1 diabetes. Diabetes Care. 2006 ; 29 : 2612-6.
 
6) Jensen DM, Korsholm L, Ovesen P, et al. Peri-conceptional A1C and risk of serious adverse pregnancy outcome in 933 women with type 1 diabetes. Diabetes Care. 2009 ; 32 : 1046-8.
 
7) Dude AM, Badreldin N, Schieler A, et al. Periconception glycemic control and congenital anomalies in women with pregestational diabetes. BMJ Open Diabetes Res Care. 2021 ; 9 : e001966.
 
8) Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation : recommendations from the international consensus on time in range. Diabetes Care. 2019 ; 42 : 1593-603.
 
P.136 掲載の参考文献
1) Holt RIG, DeVries JH, Hess-Fischl A, et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2021 ; 44 : 2589-625.
 
2) ジョン・G・ワトキンス (日本心療内科学会治療的自己評価基準作成委員会, 訳). 治療的自己-治療を効果的に進めるための医療者の心得-. 東京 : アドスリー ; 2013.
 

IV 1型糖尿病治療の実際

P.143 掲載の参考文献
1) Boden MT, Gala S. Exploring correlates of diabetes-related stress among adults with type 1 diabetes in the T1D exchange clinic registry. Diabetes Res Clin Pract. 2018 ; 138 : 211-9.
 
2) Mori H, Kuroda A, Yoshida S, et al. High prevalence and clinical impact of dynapenia and sarcopenia in Japanese patients with type 1 and type 2 diabetes : Findings from the Impact of Diabetes Mellitus on Dynapenia study. J Diabetes Investig. 2021 ; 12 : 1050-9.
 
3) Kawasaki E. Type 1 diabetes and autoimmunity. Clin Pediatr Endocrinol. 2014 ; 23 : 99-105.
 
P.150 掲載の参考文献
1) Harrington KR, Boyle CT, Miller KM, et al ; T1D Exchange Clinic Network. Management and family burdens endorsed by parents of youth < 7 years old with type 1 diabetes. J Diabetes Sci Technol. 2017 ; 11 : 980-7.
 
2) 浦上達彦, 内潟安子, 楢崎晃史, 他. 1型糖尿病における移行期医療の現状に関するアンケート調査-1型糖尿病移行期医療合同委員会報告. 糖尿病. 2020 ; 63 : 776-83.
 
3) Garvey KC, Foster NC, Agarwal S, et al. Health care transition preparation and experiences in a U.S. national sample of young adults with type 1 diabetes. Diabetes Care. 2017 ; 40 : 317-24.
 
P.170 掲載の参考文献
1) 小野智美. 「子どもの自律性 (autonomy) 」の概念分析. 日本看護科学会誌. 2004 ; 23 : 71-9.
 
2) http://www.dpeds.or.jp/uplords/files/ikouki2013_12.pdf
 
3) Cameron FJ, Garvey K, Hood KK, et al. ISPAD Clinical Practice Consensus Guidelines 2018.
 
4) Bryden KS, Peveler RC, Stein A, et al. Clinical and psychological course of diabetes from adolescence to young adulthood ; a longitudinal cohort study. Diabetes Care. 2001 ; 24 : 1536-40.
 
5) Bryden KS, Dunger DB, Mayou RA, et al. Poor prognosis of young adults with type 1 diabetes : a longitudinal study. Diabetes Care. 2003 ; 26 : 1052-7.
 
6) Laing SP, Jones ME, Swerdlow AJ, et al. Psychosocial and socioeconomic risk factors for premature death in young people with type 1 diabetes. Diabetes Care. 2005 ; 28 : 1618-23.
 
7) 浦上達彦, 内潟安子, 楢崎晃史, 他. 1型糖尿病における移行期医療の現状に関するアンケート調査-1型糖尿病移行期医療合同委員会報告. 糖尿病. 2020 ; 63 : 776-83.
 
8) http://www.nittokyo.or.jp/modules/doctor/index.php?content_id=50
 
9) http://www.jds.or.jp/modules/education/index.php?content_id=101
 
10) http://jspe.umin.jp/medical/transition.html
 
11) 南昌江. 小児・思春期糖尿病の小児科から内科への移行. 内分泌・糖尿病・代謝内科. 2014 ; 38 : 260-4.
 
P.179 掲載の参考文献
1) http://www.nittokyo.or.jp/event/patient/summer_camp/
 
2) Takii M, Uchigata Y, Tokunaga S. The duration of severe insulin omission is the factor most closely associated with the microvascular complications of Type 1 diabetic females with clinical eating disorders. Int J Eat Disord. 2008 ; 41 : 259-64.
 
P.190 掲載の参考文献
1) 西村理明, 川村智行, 菊池信行, 他. 1 型糖尿病患者 (現在20 歳以上) における日常・社会生活についての調査に関する研究 厚生労働省科学研究費補助金 (循環器疾患・糖尿病等生活習慣病対策政策研究事業) 分担研究報告書.
 
2) 厚生省・公衆衛生審議会. 生活習慣に着目した疾病対策の基本的方向性について (意見具申). 平成8年12月18日. https://www.mhlw.go.jp/www1/houdou/0812/1217-4.html (2021/10/13 閲覧)
 
3) The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 ; 14 : 977-86.
 
4) The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes : The DCCT/EDIC study 30-year follow-up. Diabetes Care. 2016 ; 39 : 686-93.
 
5) The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Mortality in type 1 diabetes in the DCCT/EDIC versus the general population. Diabetes Care. 2016 ; 39 : 1378-83.
 
6) 厚生労働省HP. 公正な採用選考の基本. https://www.mhlw.go.jp/www2/topics/topics/saiyo/saiyo1.htm (2021/10/13 閲覧)
 
7) 日本年金機構HP. 障害認定基準完成に関するもの (障害年金). https://www.nenkin.go.jp/service/pamphlet/shougainintei.html (2021/10/13 閲覧)
 
P.197 掲載の参考文献
1) Mori H, Kuroda A, Yoshida S, et al. High prevalence and clinical impact of dynapenia and sarcopenia in Japanese patients with type 1 and type 2 diabetes : Findings from the Impact of Diabetes Mellitus on Dynapenia study. J Diabetes Investig. 2021 ; 12 : 1050-9.
 
2) Komorita Y, Minami M, Maeda Y, et al. Prevalence of bone fracture and its association with severe hypoglycemia in Japanese patients with type 1 diabetes. BMJ Open Diabetes Res Care. 2021 ; 9 : e002099.
 
3) Musen G, Tinsley LJ, Marcinkowski KA, et al. Cognitive function deficits associated with long-duration type 1 diabetes and vascular complications. Diabetes Care. 2018 ; 41 : 1749-56.
 
4) Sinclair AJ, Dunning T, Dhatariya K ; an International Group of Experts. Clinical guidelines for type 1 diabetes mellitus with an emphasis on older adults : an Executive Summary. Diabet Med. 2020 ; 37 : 53-70.
 
5) Soedamah-Muthu SS, Fuller JH, Mulnier HE, et al. High risk of cardiovascular disease in patients with type 1 diabetes in the U.K. : a cohort study using the general practice research database. Diabetes Care. 2006 ; 29 : 798-804.
 
6) de Ferranti SD, de Boer IH, Fonseca V, et al. Type 1 diabetes mellitus and cardiovascular disease : a scientific statement from the American Heart Association and American Diabetes Association. Circulation. 2014 ; 130 : 1110-30.
 

書評

最近チェックした商品履歴

Loading...